Home
My Account
About Us
Forum
Contact us
الواجهة العربية
epharmaweb.com
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz
Newsletter

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



Buccolam (midazolam) approved to stop acute convulsive seizures in children


Buccolam is a medicine that contains the active substance midazolam. It is available as ‘oromucosal solution’ (a solution given in the side of the mouth, into the space between the gum and the cheek) in prefilled syringes. Each syringe contains 2.5 mg, 5 mg, 7.5 mg or 10 mg of midazolam.

Buccolam is used to stop prolonged, acute (sudden) convulsive seizures in children and adolescents (from 3 months to less than 18 years of age).

The medicine can only be obtained with a prescription.
Buccolam is given in the side of the child’s mouth. The recommended dose ranges from 2.5.mg to 10 mg, depending on the child’s age.
The full amount of the appropriate prefilled syringe should be given slowly into the space between the gum and the cheek. If necessary, the dose can be divided between both sides of the mouth.
 
When given by carers or parents Buccolam should only be used when the child has already been diagnosed with epilepsy.
Carers should only administer one dose. If the seizure has not stopped within 10 minutes of giving Buccolam, they should seek medical help immediately.
 
In infants from 3 months to less than 6 months Buccolam should only be used within a hospital and where equipment is available for resuscitation and monitoring of the patient due to an increased risk respiratory depression (inhibition of breathing).
 
The active substance in Buccolam is midazolam, a benzodiazepine, which acts as an anti-convulsant medicine. Convulsions are caused by excessive electrical activity in the brain. Buccolam attaches to the receptors for the neurotransmitter GABA in the brain and activatesthem. Neurotransmitters such as GABA are chemicals that allow nerve cells to communicate with each other. In the brain, GABA is involved in reducing the electrical activity. By activating its receptors, Buccolamincreases GABA’s effects, which will stop a convulsion.
 
The company presented results of five key studies from the published literature. These studies looked at children with acute convulsions and compared the effects of oromucosal midazolam with those of diazepam (another benzodiazepine) when given intravenously (into a vein) or rectally (into the rectum). In four of these studies, oromucosal midazolam was compared with rectal diazepam and the measure of effectiveness was the treatment’s ability to stop the seizure within 10 minutes. The fifth study compared buccal midazolam with intravenous diazepam, where the measure of effectiveness was the treatment’s ability to stop the seizure within 5 minutes.
 
Reports from the published literature confirmed that oromucosal midazolam is effective in stopping seizures in children. In the four studies, oromucosal midazolam was effective in stopping a seizure within 10 minutes in 65 to 78% of children compared with 41 to 85% of children who received rectal diazepam. When comparing buccal midazolam with intravenous diazepam, the results were also very similar.
 
The most common side effects with Buccolam (seen in more than 1 patient in 10) are sedation, somnolence (sleepiness), depressed levels of consciousness, respiratory depression and nausea (feeling sick) and vomiting.
 
Buccolam must not be used in people who may be hypersensitive (allergic) to midazolam, benzodiazepines or any of the other ingredients. It must not be used in patients with myasthenia gravis (a disease causing muscle weakness), severe respiratory insufficiency (lung conditions that cause difficulty breathing), sleep apnoea syndrome (frequent interruption of breathing during sleep) or severe liver problems.
 
Based on the results of the studies presented, the CHMP concluded that Buccolam is at least as effective as existing treatments for stopping acute prolonged, convulsive seizures in children. Although intravenous medicines may take less time to start working once injected, it takes time to gain access to the veins, especially in children. Buccolam has the advantage of being quicker and easier to administer than rectal or intravenous medicines. With regard to side effects, the medicine may cause respiratory depression, as is the case with other comparable medicines, but is generally well tolerated. The Committee therefore decided that Buccolam’s benefits are greater than its risks and recommended that it be given marketing authorisation.
 
The European Commission granted a marketing authorisation valid throughout the European Union for Buccolam on 5 September 2011.

اضغط هنا للقراءة باللغة العربية

Prepared by: Laila Nour


Source :

European Medicine Agency






Other Comments

Add a comment

You must sign in to use this servcie

Username:
Password:


facebook comments

Forgot your password


sign up

Consultants Corner

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Talal Sabouni

Dr. Talal Sabouni UROLOGY AND KIDNEY TRANSPLANT

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery
Poll

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details